FDA Approves Juvéderm VOLUMA XC For Midface Injection Via Cannula

New Allergan VOLUMA approval

Allergan has received U.S. Food and Drug Administration (FDA) approval for the use of its hyaluronic acid gel dermal filler Juvéderm VOLUMA XC with a TSK STERiGLIDE cannula for cheek augmentation to correct age-related volume deficit in the midface in adults over 21. The TSK STERiGLIDE has a unique design compared to other cannulas currently available. It offers a patented tapered tip design for easier pilot entry as well as a near-tip delivery port for more precise product placement.

Allergan Launches Online BIOCELL Resource for Patients and Surgeons

Allergan has launched, an online resource for patients, surgeons and healthcare professionals related to the voluntary global recall of BIOCELL textured breast implants and tissue expanders announced on July 24, 2019. The website offers detailed information and specific guidance about the recent announcement, including the latest resources on the BIOCELL withdrawal and warranty information.

AbbVie to Acquire Allergan

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction with an equity value of approximately $63 billion. Once the acquisiton is completed, AbbVie will continue maintain its principal executive offices in North Chicago under the leadership of current chairman and CEO Richard A. Gonzalez. Two members of Allergan’s board of directors, including chairman and CEO Brent Saunders, will join AbbVie’s board.

Allergan Launches New e-Commerce Platform for Physicians

In an effort to streamline ordering and improve customer service for its physician-customers, Allergan has launched Allergan Direct Next Gen, a streamlined e-commerce platform that offers faster and easier online product ordering and 24/7 account management. Practices can add and manage multiple users within their facilities and track orders and financial data. The mobile-enabled site was designed to improve convenience and give customers more control over their product stock, Allergan-specific promotional offers and collateral materials.

Allergan Worldwide Aesthetic Survey Highlights Trends in Aesthetic Medicine

Allergan Release Global Report

Allergan has released the results of its first worldwide medical aesthetics study, titled “Allergan 360° Aesthetics Report.” To develop the report, Allergan reached out to more than 14,500 aesthetically conscious consumers and 1,300 aesthetic physicians in 18 countries, including the United States of America, Canada, Mexico, Brazil, the United Kingdom, Spain, France, Germany, Italy, Turkey, Russia, Saudi Arabia, India, China, Japan, South Korea, Taiwan and Australia. An advisory board of physicians partnered with the company to interpret the data and compile the findings.

Allergan Launches New BOTOX Cosmetic “Own Your Look” Consumer Campaign

Botox Cosmetic Consumer Campaign

Allergan is launching a new direct-to-consumer campaign for Botox Cosmetic (onabotulinumtoxinA) entitled “Own Your Look.” The campaign is designed to address the most common concerns around BOTOX Cosmetic—fear of looking unnatural—and to encourage people to own their looks and aesthetic choices.

This is the first campaign from the brand created specifically to address millennial women and men who are increasingly curious about aesthetic treatments, while continuing to speak to the BOTOX Cosmetic core consumer (women ages 34 – 45).

Allergan Announces Results of Higher-Dose BOTOX Cosmetic for Glabellar Lines

Higher Dose Botox for Better Longevity

Higher doses of Botox Cosmetic are well tolerated and offer better longevity than the traditional 20-unit dose, according the results of a new clinical study. Allergan conducted a trial to evaluate the duration of effect and safety of Botox Cosmetic at 40, 60 and 80 unit doses versus the 20-unit dose in patients with moderate-to-severe glabellar lines. The primary efficacy endpoint of ≥1 point improvement in Facial Wrinkle Scale (FWS) from baseline was met and was statistically significant for 40, 60 and 80 units versus 20 units in 226 subjects at 24 weeks.

Allergan to Acquire Bonti

Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development: EB-001A (aesthetic) and EB-001T (therapeutic).

Allergan Launches Spotlyte Digital Hub

New consumer education hub launches

Allergan has launched Spotlyte, a digital hub of curated content designed to help consumers learn more about medical aesthetic treatments. The site features researched content, product reviews and insider profiles, together with the latest beauty news and trends. In addition to its editorial content, Spotlyte will provide consumers access to a team of trained specialists who can chat directly with anyone considering medical aesthetic treatments and help connect them to local licensed providers.